Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)
Industry: Healthcare

OFF LIST - 632 consecutive market days: OFF LIST as of 11/27/2013 Through 11/14/2016

Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.

Current Quote*
Last: $3.330
Change: 0.020
Book: $2.639
Volume: 6,185

As Of: 05/29 13:05 ET
*Quotes delayed by 20min.

Graphs for MACK

3 Month Graph

6 Month Graph

1 Year Graph